hVIVO (LON:HVO) Announces Quarterly Earnings Results

hVIVO (LON:HVO) released its quarterly earnings results on Tuesday. The company reported GBX (0.82) earnings per share for the quarter, Digital Look Earnings reports. hVIVO had a negative return on equity of 17.06% and a negative net margin of 12.48%.

hVIVO Price Performance

Shares of HVO traded down GBX 0.10 during trading hours on Friday, reaching GBX 5.90. 877,454 shares of the company traded hands, compared to its average volume of 2,532,274. The company has a quick ratio of 1.16, a current ratio of 1.21 and a debt-to-equity ratio of 43.38. The stock has a market capitalization of £40.62 million, a PE ratio of -6.78 and a beta of 1.69. hVIVO has a fifty-two week low of GBX 4.30 and a fifty-two week high of GBX 11. The stock has a fifty day simple moving average of GBX 6.75 and a 200 day simple moving average of GBX 7.36.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.